Eniya Beemarajan
Researcher
Also affiliated: Arkansas Children's Hospital (2023–2024)
Unknown Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Eniya Beemarajan's research focuses on neurological disorders, particularly dystonia in children. Her work investigates genetic factors contributing to these conditions, as indicated by her involvement in studies related to <i>KMT2B</i>-related dystonia. Beemarajan has co-authored publications examining specific genetic mutations and their clinical manifestations in young patients, including those with worsening gait abnormalities. Her research also touches upon the safety and adverse effects of medical interventions, such as gene therapy, as seen in a publication addressing acute liver injury following a specific gene therapy treatment. Beemarajan collaborates with researchers at the University of Arkansas for Medical Sciences, including Aravindhan Veerapandiyan, Praveen Kumar Ramani, Ruthwik Duvuru, and Megan W. Butler, with whom she has co-authored multiple publications.
Metrics
- h-index: 2
- Publications: 3
- Citations: 11
Selected Publications
-
GAD65 Antibody–Associated Epilepsy and Autoimmune Encephalitis in Children and Young Adults: A Single-Center Case Series and Review of Literature (2026)
-
Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Requiring Intravenous Immunoglobulin (2024)
Collaboration Network
Top Collaborators
- Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Requiring Intravenous Immunoglobulin
- Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Requiring Intravenous Immunoglobulin
- Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Requiring Intravenous Immunoglobulin
- Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Requiring Intravenous Immunoglobulin
- Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Requiring Intravenous Immunoglobulin
- Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Requiring Intravenous Immunoglobulin
- Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Requiring Intravenous Immunoglobulin
- Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Requiring Intravenous Immunoglobulin
- Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Requiring Intravenous Immunoglobulin
Similar Researchers
Based on overlapping research topics